Payment overview · 2025
General Payments
$56.21
3 reported records · 2 companies
Healthcare provider profile · identity verified
Timothy Conlon, DO
Allopathic & Osteopathic Physicians|Internal Medicine · HOLLAND, MI · NPI 1043250129
Verified facts
What the public records show
CMS Open Payments records show Timothy Conlon, DO received $56.21 in general payments during 2025 across 3 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 75.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.62 | 75.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.59 | 24.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $37.36 | 2 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.62 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 657 | 170 |
| Lisinopril | Lisinopril | 578 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 503 | 126 |
| Losartan Potassium | Losartan Potassium | 409 | 109 |
| Omeprazole | Omeprazole | 312 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 65 |
| Metformin Hcl | Metformin Hcl | 216 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 58 |
| Simvastatin | Simvastatin | 209 | 50 |
| Meloxicam | Meloxicam | 200 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 51 |
| Sertraline Hcl | Sertraline Hcl | 166 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 45 |
| Furosemide | Furosemide | 150 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 36 |
| Prednisone | Prednisone | 145 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 39 |
| Metformin Hcl Er | Metformin Hcl | 133 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 35 |
| Trazodone Hcl | Trazodone Hcl | 125 | 30 |
| Carvedilol | Carvedilol | 118 | 28 |
| Allopurinol | Allopurinol | 117 | 33 |
| Alprazolam | Alprazolam | 117 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 29 |
| Gabapentin | Gabapentin | 108 | 35 |
| Finasteride | Finasteride | 97 | 24 |
| Eliquis | Apixaban | 96 | 22 |
| Potassium Chloride | Potassium Chloride | 91 | 20 |
| Tramadol Hcl | Tramadol Hcl | 87 | 25 |
| Xarelto | Rivaroxaban | 86 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 20 |
| Jardiance | Empagliflozin | 75 | 14 |
| Spironolactone | Spironolactone | 75 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 17 |
| Trulicity | Dulaglutide | 72 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 33 |
| Prazosin Hcl | Prazosin Hcl | 56 | 13 |
| Topiramate | Topiramate | 56 | 16 |
| Atenolol | Atenolol | 55 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 20 |
| Montelukast Sodium | Montelukast Sodium | 52 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 19 |
| Lorazepam | Lorazepam | 45 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 15 |
| Meclizine Hcl | Meclizine Hcl | 39 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 32 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Dulera | Mometasone/Formoterol | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 24 | suppressed |
| Pulmicort Flexhaler | Budesonide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Glyburide | Glyburide | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Ozempic | Semaglutide | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Benzonatate | Benzonatate | 13 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $56.21 · 3 records | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE, Ozempic, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error